Peer Review History

Original SubmissionJune 5, 2023
Decision Letter - Zhi Ruan, Editor

PONE-D-23-15982Population structure of community-acquired extended-spectrum beta-lactamase producing Escherichia coli and methicillin resistant Staphylococcus aureus in a French region showed no difference between urban and rural areasPLOS ONE

Dear Dr. Biguenet,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 25 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Zhi Ruan, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following financial disclosure: 

"This study was funded by the CHU of Besançon (API-CHU 2019)"

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Antimicrobial resistance is an urgent global public health threat,with high mortality rates due to infections caused by multidrug-resistant bacteria. Understanding the molecular epidemiology of multidrug-resistant bacteria acquired in the community is crucial for effectively preventing and controlling infections caused by these resistant strains.

There are also some major concerns,

1. In line 74, the authors mentioned conducting a prospective multicenter study. It is unclear whether this study underwent ethical review. Moreover, the sampling methods and detailed information regarding the samples have not been specified.

2. In Figure 1, it would be helpful to annotate each circle with specific information to indicate what each circle represents.

3. Do the authors analyze the MLST of the MRSA isolates?

4. Do the authors compare the evolutionary changes of multidrug-resistant bacteria between 2019 and 2021 in the region?

Reviewer #2: Biguenet et al. has performed a population structure/genomic analysis of ESBL producing E. coli and MRSA isolates in France - reporting the prevalence of STs and AMR genes. The authors has also studied the distribution of these characteristics in relation to the region/areas based on population size. In general the study was interesting and important to public health, and the MS was well written. However, the classification of three areas such as urban and rural was quite arbitrary, and not convincing.

Major questions:

1. line 79: population size was not the only factor. other factors such as anthropogenic activities, animal farming, agriculture, or winery would be more relevant to the relationship of isolates under one health approach. So the authors did not know where the patients were from?

2. line 169-170: The association of ESBLs and plasmids was not based on solid methodology, as only short-read sequencing data were used to determine the genetic location of these genes. Multicopy insertion elements may fragment the short-read assemblies into multiple contigs, and reconstruction of ESBL plasmids requires additional experiments, such as long-read sequencing or PCR gap closure.

3. Line 298-304: The lack of clinical data or relevant metadata had weakened the discussion and entire investigation. It was unusual that the origin of these isolates were unknown. Without knowing the source, all the discussion was kind of speculation, even though Ec ST131 tended to be circulated among the communities. Was the study supported by the ethical board?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer #1:

Antimicrobial resistance is an urgent global public health threat, with high mortality rates due to infections caused by multidrug-resistant bacteria. Understanding the molecular epidemiology of multidrug-resistant bacteria acquired in the community is crucial for effectively preventing and controlling infections caused by these resistant strains.

There are also some major concerns,

1. In line 74, the authors mentioned conducting a prospective multicenter study. It is unclear whether this study underwent ethical review. Moreover, the sampling methods and detailed information regarding the samples have not been specified.

The study was approved by the local ethic committee before the study commencement considering that no patients data were collected and samples were anonymised. This was added in the text line 74. Information regarding samples were specified in Lines 77-80.

2. In Figure 1, it would be helpful to annotate each circle with specific information to indicate what each circle represents.

The colors are listed in the figure legend from the inner circle to the outer circle.

3. Do the authors analyze the MLST of the MRSA isolates?

We chose to analyse complex clones (CC) rather than sequence types (ST) due to the small size of our population. The results of the MLST analysis are available in the supplementary data.

4. Do the authors compare the evolutionary changes of multidrug-resistant bacteria between 2019 and 2021 in the region?

We observed no difference between 2019 and 2021 for phylogroups (p = 0.36), sequence type (p = 0.153) and for the ESBL gene (p = 0.092) in our Escherichia coli strains. For Staphylococcus aureus, we observed no difference for the complex clonal (p = 0.107) or the SCCmec cassette (p = 0.096). This was added in the text line 135 and line 204.

Reviewer #2:

Biguenet et al. has performed a population structure/genomic analysis of ESBL producing E. coli and MRSA isolates in France - reporting the prevalence of STs and AMR genes. The authors has also studied the distribution of these characteristics in relation to the region/areas based on population size. In general the study was interesting and important to public health, and the MS was well written. However, the classification of three areas such as urban and rural was quite arbitrary, and not convincing.

Major questions:

1. Line 79: population size was not the only factor. other factors such as anthropogenic activities, animal farming, agriculture, or winery would be more relevant to the relationship of isolates under one health approach. So the authors did not know where the patients were from?

No patient data were collected, so we agree with the reviewer that the location of the laboratory is a distant proxy of patient environment and anthropogenic activities. This limitation is addressed in the discussion section.

2. Line 169-170: The association of ESBLs and plasmids was not based on solid methodology, as only short-read sequencing data were used to determine the genetic location of these genes. Multicopy insertion elements may fragment the short-read assemblies into multiple contigs, and reconstruction of ESBL plasmids requires additional experiments, such as long-read sequencing or PCR gap closure.

We agree that short reads do not allow total plasmid reconstruction. We have used PlaScope here, a tool to predict whether the contigs from short read data in our fasta file are from chromosome, plasmid or unclassified location. PlaScope uses Centrifuge and a custom database of chromosome and plasmid sequences to classify the contigs. PlasScope is not able to reconstruct the plasmid or predict if 2 contigs are from the same or different plasmids.

Other tools are also available to distinguish between plasmid and short read contigs:

- Robertson J and Nash J. RFPlasmid: predicting plasmid sequences from short-read

data using machine learning. Microbial Genomics. 2018. DOI: 10.1099/mgen.0.000683

- van der Graaf-van Bloois et al. MOB-suite: software tools for clustering, reconstruction and typing of plasmids from draft assemblies. Microbial Genomics. 2021. DOI: 10.1099/mgen.0.000206 (nécessaire ces 2 citations ?)

3. Line 298-304: The lack of clinical data or relevant metadata had weakened the discussion and entire investigation. It was unusual that the origin of these isolates were unknown. Without knowing the source, all the discussion was kind of speculation, even though Ec ST131 tended to be circulated among the communities. Was the study supported by the ethical board?

We agree with the reviewer that the lack of clinical data is the major limitation of our study and we underlined this point in the discussion. However, we have collected all consecutive ESBLE and MRSA isolates in a large number of private community laboratories, and it is very likely that our results reflect population structures of ESBLE and MRSA in our region. Moreover, such data are not frequently available in the community sector.

The study was approved by the local ethic committee before the study commencement considering that no patients data were collected and samples were anonymised

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Zhi Ruan, Editor

Population structure of community-acquired extended-spectrum beta-lactamase producing Escherichia coli and methicillin resistant Staphylococcus aureus in a French region showed no difference between urban and rural areas

PONE-D-23-15982R1

Dear Dr. Biguenet,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Zhi Ruan, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: All the questions have been addressed in the revised manuscript. An ethical statement has been included in the methods

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Tian Jiang

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Zhi Ruan, Editor

PONE-D-23-15982R1

Population structure of community-acquired extended-spectrum beta-lactamase producing Escherichia coli and methicillin resistant Staphylococcus aureus in a French region showed no difference between urban and rural areas

Dear Dr. Biguenet:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Zhi Ruan

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .